C WorldWide Group Holding A S Has $26.34 Million Stock Holdings in Insmed, Inc. $INSM

C WorldWide Group Holding A S boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 18.4% in the first quarter, HoldingsChannel reports. The firm owned 161,110 shares of the biopharmaceutical company’s stock after purchasing an additional 25,000 shares during the quarter. Insmed accounts for about 0.6% of C WorldWide Group Holding A S’s holdings, making the stock its 26th largest holding. C WorldWide Group Holding A S’s holdings in Insmed were worth $26,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in Insmed by 65.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 263 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Insmed by 80.8% during the second quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after acquiring an additional 21,176 shares during the period. Baird Financial Group Inc. bought a new stake in shares of Insmed during the second quarter worth approximately $2,589,000. Amundi grew its position in shares of Insmed by 21,194.4% in the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 11,445 shares during the last quarter. Finally, Natixis acquired a new position in shares of Insmed in the second quarter valued at approximately $1,072,000.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the transaction, the chief operating officer directly owned 98,603 shares in the company, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the sale, the chief financial officer directly owned 69,082 shares in the company, valued at approximately $7,065,016.14. This trade represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 54,590 shares of company stock valued at $5,793,738 over the last three months. 2.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on INSM. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. Wells Fargo & Company boosted their target price on shares of Insmed from $160.00 to $161.00 and gave the company an “overweight” rating in a research report on Wednesday. Leerink Partners upped their price target on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. Stifel Nicolaus raised their price target on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Raymond James Financial assumed coverage on shares of Insmed in a research note on Friday, April 10th. They issued an “outperform” rating and a $200.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $211.05.

Insmed Trading Down 2.1%

Shares of Insmed stock opened at $107.46 on Friday. The firm’s 50 day moving average is $105.58 and its 200 day moving average is $136.11. The firm has a market capitalization of $23.29 billion, a PE ratio of -18.69 and a beta of 0.78. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the prior year, the firm earned ($1.42) EPS. The firm’s revenue was up 229.7% compared to the same quarter last year. Equities research analysts forecast that Insmed, Inc. will post -2.52 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.